MA40589A - Utilisation de jagged 1/frizzled 4 à titre de marqueurs de surface cellulaire pour isoler des cellules progénitrices ventriculaires cardiaques humaines - Google Patents
Utilisation de jagged 1/frizzled 4 à titre de marqueurs de surface cellulaire pour isoler des cellules progénitrices ventriculaires cardiaques humainesInfo
- Publication number
- MA40589A MA40589A MA040589A MA40589A MA40589A MA 40589 A MA40589 A MA 40589A MA 040589 A MA040589 A MA 040589A MA 40589 A MA40589 A MA 40589A MA 40589 A MA40589 A MA 40589A
- Authority
- MA
- Morocco
- Prior art keywords
- progenitor cells
- frizzled
- jagged
- ventricular progenitor
- ventricular
- Prior art date
Links
- 210000000130 stem cell Anatomy 0.000 title abstract 10
- 230000002861 ventricular Effects 0.000 title abstract 10
- 102000001003 Frizzled-4 Human genes 0.000 title abstract 7
- 108050007986 Frizzled-4 Proteins 0.000 title abstract 7
- 102000049556 Jagged-1 Human genes 0.000 title abstract 7
- 108700003486 Jagged-1 Proteins 0.000 title abstract 7
- 108700037966 Protein jagged-1 Proteins 0.000 title abstract 7
- 210000004027 cell Anatomy 0.000 title abstract 2
- 102100024392 Insulin gene enhancer protein ISL-1 Human genes 0.000 abstract 3
- 108010090448 insulin gene enhancer binding protein Isl-1 Proteins 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 230000000747 cardiac effect Effects 0.000 abstract 2
- 206010048610 Cardiotoxicity Diseases 0.000 abstract 1
- 230000001625 cardiomyogenic effect Effects 0.000 abstract 1
- 231100000259 cardiotoxicity Toxicity 0.000 abstract 1
- 230000007681 cardiovascular toxicity Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000004217 heart function Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 210000000663 muscle cell Anatomy 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 238000000926 separation method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/42—Notch; Delta; Jagged; Serrate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/03—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from non-embryonic pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462040892P | 2014-08-22 | 2014-08-22 | |
| US201562194016P | 2015-07-17 | 2015-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA40589A true MA40589A (fr) | 2017-06-28 |
Family
ID=54062813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA040589A MA40589A (fr) | 2014-08-22 | 2015-08-21 | Utilisation de jagged 1/frizzled 4 à titre de marqueurs de surface cellulaire pour isoler des cellules progénitrices ventriculaires cardiaques humaines |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10597637B2 (enExample) |
| EP (2) | EP3183337B1 (enExample) |
| JP (2) | JP6738808B2 (enExample) |
| DK (1) | DK3183337T3 (enExample) |
| MA (1) | MA40589A (enExample) |
| WO (1) | WO2016029122A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10596200B2 (en) | 2014-08-22 | 2020-03-24 | Procella Therapeutics Ab | Use of LIFR or FGFR3 as a cell surface marker for isolating human cardiac ventricular progenitor cells |
| DK3183337T3 (en) | 2014-08-22 | 2019-04-01 | Procella Therapeutics Ab | Use of Jagged 1 / Frizzled 4 as cell surface marker for isolation of human cardiac ventricular progenitor cells |
| WO2017172086A1 (en) * | 2016-02-19 | 2017-10-05 | Leung Chuen Yan | Genetic markers for engraftment of human cardiac ventricular progenitor cells |
| WO2017192606A1 (en) * | 2016-05-02 | 2017-11-09 | Emory University | Methods of producing specialized cardio-like cells from stem cell |
| US11352604B2 (en) * | 2016-09-30 | 2022-06-07 | Wisconsin Alumni Research Foundation | Method of making cardiomyocytes from human pluripotent cells |
| US10508263B2 (en) * | 2016-11-29 | 2019-12-17 | Procella Therapeutics Ab | Methods for isolating human cardiac ventricular progenitor cells |
| US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
| WO2019038587A1 (en) | 2017-08-23 | 2019-02-28 | Procella Therapeutics Ab | USE OF NEUROPILIN-1 (NRP1) AS A CELL SURFACE MARKER FOR ISOLATING HUMAN CARDIAC VENTRICULAR PROGENITOR CELLS |
| CN109189051A (zh) * | 2018-10-29 | 2019-01-11 | 江苏罗思韦尔电气有限公司 | 一种基于T-Box的故障存储及处理方法 |
| WO2023278382A1 (en) | 2021-06-29 | 2023-01-05 | Staffan Holmin | Endoluminal delivery cannula |
| EP4402249A1 (en) * | 2021-09-13 | 2024-07-24 | Fujifilm Cellular Dynamics, Inc. | Methods for the production of committed cardiac progenitor cells |
| US20230330264A1 (en) | 2022-04-15 | 2023-10-19 | Smartcella Solutions Ab | COMPOSITIONS AND METHODS FOR EXOSOME-MEDIATED DELIVERY OF mRNA AGENTS |
| GB202314218D0 (en) | 2023-09-18 | 2023-11-01 | Astrazeneca Ab | Cell therapy |
| CN118897089B (zh) * | 2024-08-09 | 2026-02-17 | 山西医科大学 | Sarcolipin在早期无创诊断I型射血分数保留性心衰中的应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| US5561384A (en) | 1995-11-08 | 1996-10-01 | Advanced Micro Devices, Inc. | Input/output driver circuit for isolating with minimal power consumption a peripheral component from a core section |
| US5994619A (en) | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
| US5945577A (en) | 1997-01-10 | 1999-08-31 | University Of Massachusetts As Represented By Its Amherst Campus | Cloning using donor nuclei from proliferating somatic cells |
| US7166280B2 (en) | 2000-04-06 | 2007-01-23 | Franco Wayne P | Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease |
| EP1435977A4 (en) | 2001-09-19 | 2005-06-08 | Ford Henry Health System | HEART TRANSPLANTATION OF STEM CELLS FOR THE TREATMENT OF HEART FAILURE |
| CA2514810A1 (en) | 2003-01-31 | 2004-08-19 | The Regents Of The University Of California | Use of islet 1 as a marker for isolating or generating stem cells |
| US20080038229A1 (en) | 2006-08-08 | 2008-02-14 | Minguell Jose J | Intracoronary injection of a mixture of autologous bone marrow derived mononuclear cells and autologous bone marrow derived mesenchymal stem cells for utilization and rescue of infarcted myocardium |
| US20100166714A1 (en) | 2006-11-02 | 2010-07-01 | The General Hospital Corporation | Cardiovascular stem cells, methods for stem cell isolation, and uses thereof |
| WO2008058273A2 (en) | 2006-11-09 | 2008-05-15 | The Johns Hopkins University | Dedifferentiation of adult mammalian cardiomyocytes into cardiac stem cells |
| US20080182328A1 (en) | 2006-12-19 | 2008-07-31 | The Burnham Institute | Mammalian extraembryonic endoderm cells and methods of isolation |
| JP2010517578A (ja) | 2007-02-09 | 2010-05-27 | ザ ジェネラル ホスピタル コーポレイション | Ｉｓｌｅｔ１＋系統に入るように細胞を誘導する方法およびそれを拡大する方法 |
| WO2009017460A1 (en) | 2007-07-31 | 2009-02-05 | Es Cell International Pte Ltd | Method for identifying and selecting cardiomyocytes |
| EP2245140A2 (en) * | 2007-11-30 | 2010-11-03 | New York Medical College | Compositions comprising hdac inhibitors and methods of their use in restoring stem cell function and preventing heart failure |
| WO2010042856A2 (en) | 2008-10-09 | 2010-04-15 | The General Hospital Corporation | Tissue engineered myocardium and methods of production and uses thereof |
| WO2011091945A1 (en) | 2010-01-26 | 2011-08-04 | Université Libre de Bruxelles | Tools for isolating and following cardiovascular progenitor cells |
| US20130209415A1 (en) * | 2010-06-03 | 2013-08-15 | The Board Of Trustees Of The Leland Stanford Junior University | Purified compositions of cardiovascular progenitor cells |
| US20120009158A1 (en) * | 2010-06-18 | 2012-01-12 | The General Hospital Corporation | VENTRICULAR INDUCED PLURIPOTENT STEM (ViPS) CELLS FOR GENERATION OF AUTOLOGOUS VENTRICULAR CARDIOMYOCYTES AND USES THEREOF |
| WO2012070014A2 (en) | 2010-11-26 | 2012-05-31 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Identification of novel cell surface markers for pancreatic progenitor cells and definite endodermal cells |
| WO2012162741A1 (en) * | 2011-06-01 | 2012-12-06 | Monash University | Enrichment of cardiomyocytes |
| US8951798B2 (en) | 2011-10-13 | 2015-02-10 | Wisconsin Alumni Research Foundation | Generation of cardiomyocytes from human pluripotent stem cells |
| JP5920741B2 (ja) | 2012-03-15 | 2016-05-18 | ｉＨｅａｒｔ Ｊａｐａｎ株式会社 | 人工多能性幹細胞から心筋および血管系混合細胞群を製造する方法 |
| US9234176B2 (en) | 2012-11-13 | 2016-01-12 | The Board Of Trustees Of The Leland Stanford Junior University | Chemically defined production of cardiomyocytes from pluripotent stem cells |
| WO2014150602A1 (en) | 2013-03-15 | 2014-09-25 | Fate Therapeutics, Inc. | Cell potency assay for therapeutic potential |
| US10888588B2 (en) | 2013-10-18 | 2021-01-12 | Icahn School Of Medicine At Mount Sinai | Directed cardiomyocyte differentiation and ventricular specification of stem cells |
| ES2689804T3 (es) | 2013-11-20 | 2018-11-15 | Miltenyi Biotec Gmbh | Composiciones de subpoblaciones de cardiomiocitos |
| EP3105253B1 (en) * | 2014-02-12 | 2018-06-27 | F. Hoffmann-La Roche AG | Anti-jagged1 antibodies and methods of use |
| WO2015166638A1 (ja) * | 2014-05-01 | 2015-11-05 | ｉＨｅａｒｔ Ｊａｐａｎ株式会社 | Ｃｄ８２陽性心筋前駆細胞 |
| DK3183337T3 (en) | 2014-08-22 | 2019-04-01 | Procella Therapeutics Ab | Use of Jagged 1 / Frizzled 4 as cell surface marker for isolation of human cardiac ventricular progenitor cells |
| US10596200B2 (en) | 2014-08-22 | 2020-03-24 | Procella Therapeutics Ab | Use of LIFR or FGFR3 as a cell surface marker for isolating human cardiac ventricular progenitor cells |
| WO2016131137A1 (en) | 2015-02-17 | 2016-08-25 | University Health Network | Methods for making and using sinoatrial node-like pacemaker cardiomyocytes and ventricular-like cardiomyocytes |
| WO2017172086A1 (en) | 2016-02-19 | 2017-10-05 | Leung Chuen Yan | Genetic markers for engraftment of human cardiac ventricular progenitor cells |
| US10508263B2 (en) | 2016-11-29 | 2019-12-17 | Procella Therapeutics Ab | Methods for isolating human cardiac ventricular progenitor cells |
-
2015
- 2015-08-21 DK DK15759585.1T patent/DK3183337T3/en active
- 2015-08-21 WO PCT/US2015/046309 patent/WO2016029122A1/en not_active Ceased
- 2015-08-21 EP EP15759585.1A patent/EP3183337B1/en active Active
- 2015-08-21 JP JP2017529972A patent/JP6738808B2/ja active Active
- 2015-08-21 MA MA040589A patent/MA40589A/fr unknown
- 2015-08-21 US US14/832,324 patent/US10597637B2/en active Active
- 2015-08-21 EP EP18211720.0A patent/EP3524673A1/en active Pending
-
2020
- 2020-04-22 JP JP2020076020A patent/JP2020120677A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020120677A (ja) | 2020-08-13 |
| EP3183337A1 (en) | 2017-06-28 |
| EP3183337B1 (en) | 2019-02-06 |
| US10597637B2 (en) | 2020-03-24 |
| JP6738808B2 (ja) | 2020-08-12 |
| US20160053229A1 (en) | 2016-02-25 |
| WO2016029122A1 (en) | 2016-02-25 |
| EP3524673A1 (en) | 2019-08-14 |
| DK3183337T3 (en) | 2019-04-01 |
| JP2017525393A (ja) | 2017-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201290527A1 (ru) | Способы выделения мононуклеарных клеток, которые включают субпопуляцию мезенхимальных клеток-предшественников, и сосудистых клеток, которые включают субпопуляцию эндотелиальных клеток-предшественников, из пуповинной ткани | |
| EP4606890A3 (en) | Antigen-presenting cell-mimetic scaffolds and methods for making and using the same | |
| EA202091219A1 (ru) | Культивирование плаценты с целью выделения экзосом | |
| EA202091333A1 (ru) | Способы активации, модификации и экспансии t-клеток для лечения рака и связанных с ним злокачественных заболеваний | |
| MY192522A (en) | Defined composition gene modified t-cell products | |
| MX2016011686A (es) | Composiciones utiles en el tratamiento de deficiencia de la ornitina transcarbamilasa (otc). | |
| MX2013000958A (es) | Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma. | |
| MX390083B (es) | Formulaciones de (r)-2-amino-3-fenilpropil carbamato. | |
| MX2017013562A (es) | Reguladores de microbioma y usos relacionados de los mismos. | |
| MX2018001363A (es) | Derivados del mononucleotido de nicotinamida y sus usos. | |
| EP4640273A3 (en) | Inducible caspases and methods for use | |
| EA201790357A1 (ru) | Способ получения клеток-предшественников зрелой печени | |
| MX366152B (es) | Modulacion por hutc de mediadores proinflamatorios de pulmon y enfermedades y trastornos pulmonares. | |
| CA3011049A1 (en) | Compositions for linking dna-binding domains and cleavage domains | |
| MX2019007890A (es) | Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte. | |
| WO2015181831A3 (en) | A method for targettingglioblastoma with wharton jelly-mesenchymal stem cells (wj-msc) derived from human umbilical cord | |
| MX2022003039A (es) | Metodo de seleccion de donantes universales para identificar donantes de celulas nk. | |
| EP4497477A3 (en) | Improved synthesis of the radiolabeled prostate-specific membrane antigen (psma) inhibitor [18f]dcfpyl | |
| MX2021006515A (es) | Composiciones de methylobacterium para mejorar el rendimiento del maíz. | |
| MX377300B (es) | Terapia con células madre en patologías endometriales. | |
| HK1251623A1 (zh) | T细胞耗尽或缺乏t细胞共刺激的检测及其用途 | |
| WO2018140850A3 (en) | T cells derived from umbilical cord blood | |
| WO2020036646A3 (en) | Cancer neoantigens and their utilities in cancer vaccines and tcr-based cancer immunotherapy | |
| PH12016501689B1 (en) | Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof | |
| ZA201908062B (en) | Selection and use of umbilical cord cell fractions suitable for transplantation |